Method of screening for chaperonin modulator

Patent metadata

Field	Value
Publication number	US-9260717-B2
Application number	US-201214115730-A
Country	US
Kind code	B2
Filing date	Aug 20, 2012
Priority date	Aug 24, 2011
Publication date	Feb 16, 2016
Grant date	Feb 16, 2016

Abstract

The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target. Furthermore, by using the screened material, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease may be effectively prevented or treated without concern for cell death due to autophagy, which is the existing method of removing protein aggregate.

First claim

The invention claimed is:

1. A method of screening for a CCT4 modulator, the method comprising
1) preparing a candidate material and VRK2;
2) measuring an expression amount or a kinase activity of the VRK2;
3) treating the VRK2 with the candidate material and measuring a change in the expression amount or the kinase activity of the VRK2; and
4) determining the candidate material as the CCT4 modulator by comparing the expression amount or the kinase activity of VRK2 between the treated and untreated groups.

2. The method according to claim 1 , wherein the CCT4 modulator increases an expression amount or a stability of CCT4 protein, and
the step 4) is performed by identifying the candidate material as a material that increases the expression amount or the stability of CCT4 protein if the expression amount or the kinase activity of VRK2 is decreased compared to untreated group.

3. The method according to claim 1 , wherein the CCT4 modulator decreases an expression amount or a stability of CCT4 protein, and
the step 4) is performed by identifying the candidate material as a material that decreases the expression amount or stability of CCT4 protein if the expression amount or the kinase activity of VRK2 is increased compared to untreated group.

Assignees

• Kim Kyong Tai
• Kim Sangjune
• Postech Acad Ind Found

Inventors

• Kim Kyong Tai
• Kim Sangjune

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• C12N15/1137 Primary

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title